|
|
Sitemap
-
Technical Analysis
-
IM / Email Alerts
-
Performance
-
Book Images
-
Book Images Sign Up
-
Mobile1
-
BioRunUp Store
-
About The Service
-
Webinars
-
BioRunUp Trade Alerts - Thank You!
-
BioRunUp Chat
-
Video Library
-
User's Guide
-
Email Subscription
-
Historical FDA Tracker
-
FAQS
-
Clinical and Regulatory Catalyst Calendar
-
Mike's Trading Account
-
The Run-Up Method
-
Mark's Trading Account
-
Valuation Studies
-
Affiliate Program
-
Testimonials
-
Disclaimer
-
Members Only Forum
-
FDA Calendar
-
SMS Text Alerts
-
Weekly Newsletter
-
Email BioRunUp
-
Email Alerts
-
Catalyst Roadmap
-
Analyst Reports
-
Articles
-
Do Not Panic
-
ALXA - What is Going On?
-
MELA Panic May Provide Excellent Entry Price for November Run-Up
-
Sanofi-Aventis's Prowl for New Insulin, Could it be Biodel's Linjeta?
-
ISTA - PDUFA Date of 10/16/10 Quickly Approaching
-
The Charts Don't Lie
-
EXAS – An Amazing Run-Up
-
BioRunUp to Present at Timothy Sykes Conference
-
AVNR Analyst Upgrades May Propel Run-Up
-
ALXA and JAZZ Receive CRLs
-
ALKS Gains FDA Approval
-
BioRunUp.com Launches an Exciting New Service
-
Bio-Analysis
-
BioRunUp Members- Sign up for SMS Alerts
-
ISTA - PDUFA Date of 10/16/10 Rapidly Approaching
-
BioRunUp / mikehavRx Merger: More Resources to Profit from FDA, Clinical Trial Binary Events
-
Bio-Catalyst Stock Notes: $ASTM $AMRN $BIOD $LCI $PATH $RPTP
-
$EXAS - BioRunUp Game Plan
-
What Can We Learn from ALKS, QCOR, and ISTA?
-
MELA Valuation Report Released
-
New Feature: BioRunUp News Feed
-
New Feature: Historical FDA Tracker
-
Detecting More Upside Potential for EXACT Sciences (NASDAQ:EXAS)
-
ARNA Receives a CRL from the FDA
-
Run-Up Analysis: ALXA, AVNR, and BIOD
-
Polls: EXAS, VVUS, AVNR, and BIOD Catalysts
-
BioRunUp Run-Up Valuation Report for MNKD Released
-
EXAS - Playing the Validation Results
-
EXAS Validation Results Released
-
A Method to Profit From FDA Approvals
-
BioRunUp Recommended AVNR Options Trade Up Over 116%
-
Run-Up Play for January 2011
-
BioRunUp Live Trades
-
NuPathe (NASDAQ:PATH) Seeks FDA Approval for Migraine Skin Patch
-
To Those Who Have Yet to Subscribe:
-
$AMRN Amarin Moves Up Clinical Timelines, Again
-
$CBRX Columbia Labs Cleans up Balance Sheet Ahead of Pivotal Study Results
-
A Quick Note Regarding AMRN
-
AMRN Up Over 20% Since BioRunUp Text Message Alert
-
$RPTP Raptor Pharma Seeks to Profit from Treating Rare Disorders
-
$MELA's Advisory Panel Recommendation Presents Trading Opportunities
-
$CPD Caraco Pharma Labs: Generic Drug Value, Turnaround Play
-
Overview and Analysis of Drug / Device Development Process
-
$NEOP Detecting Upside Potential for Neoprobe Ahead of Pivotal Study Results
-
$RMTI Rockwell Medical Poised to Benefit from $AMAG Iron Drug Safety Concerns
-
Valuation Report for CBRX Released
-
$AMRN Amarin to Report Pivotal MARINE Study Results on Monday
-
This Week's Watchlist 11/29/10
-
$AMRN Amarin Exceeds Expectations in Pivotal Study, Expedites Projected FDA Filing
-
$CPIX Cumberland Pharma Displaying Bullish Technical Position: Promising for a Breakout
-
BioRunUp's Pick of AMRN up 130% / Now Offering New $49 Monthly Plan
-
$KERX Keryx Faces Key Litmus Test with Phase 3 Efficacy Results on Tuesday for Zerenex
-
$OREX Orexigen Remains Stuck in a Range: Potential Break Upward
-
A Request from BioRunUp.com
-
$PLX Protalix BioTherapeutics: Possible Momentum Play
-
Quick Reminder- OREX FDA Advisory Panel is next week
-
$30M Cap Company with Cancer Drugs Awaits its NDA from the FDA
-
Private Twitter Account Created ONLY for BioRunUp Paid Subscribers
-
$ENDP Endo Pharma Showing Signs of Weakness
-
Utilize the Private Twitter Feed @BioRunUpTrades
-
$LCI Lannett Profit Taking Represents Buying Opportunity
-
$LCI Lannett Spooks Investors with Plans for Public Stock Offering
-
$LCI Lannett Prices Stock Offering Ahead of Expected FDA Decision
-
$ANX Requests a Meeting with the FDA for a New Product- ANX-514
-
DEPO Valuation Report Released
-
Twitter Trade Alerts Now Available for BioRunUp Mobile App
-
This Week's Watchlist 12/20/10
-
ACUR Submits an NDA for ACUROX Tablets
-
Mid-Week Update
-
This Week's Watchlist 12/27/10
-
DEPO Continues its Amazing Run-Up
-
$PLX Protalix BioTherapeutics: Update on Potential Targets and Taking Profits
-
$PTIE - Pain Therapeutics Refiles NDA for Remoxy
-
BioRunUp Apparel
-
This Week's Watchlist 1/3/11
-
Free Tool for Traders
-
Creating Your Own Watchlist Calendar
-
Understanding NDA Filings
-
CYTK - Cytokinetics Upcoming Clinical Trial Data
-
Video - PLX Trade Review
-
$ENMD EntreMed: Pullback in the Recent Bullish Trend
-
$FCSC ($10M Cap) Files Response to CRL - possible PDUFA date of 6/22/11
-
This Week's Watchlist 1/10/11
-
$ALKS Alkermes, Inc.: Breakout Potential
-
$PLX Shelf Registration Confusion Creates Entry Opportunity
-
GTHP - Likely FDA Panel for Cervical Cancer Diagnostics Test
-
Regenicin - Several FDA and Clinical Trial Catalysts Pending
-
$DCTH Delcath Systems, Inc - Finding support in key area
-
FCSC - In Depth Analysis and RunUp Target
-
$FCSC Dilutes- What Now?
-
$XNPT XenoPort, Inc.: Daily Chart Pointing Up, Weekly Still Pointing Down
-
$RGIN - Regenicin Investors Presentation
-
Reminder About Using BioRunUpTrades
-
An "Unbiased" Analysis of Regenicin $RGIN
-
Shares of $MNKD continue to drop after CRL
-
$PTIE gets NDA Accepted by the FDA
-
$PLX Protalix BioTherapeutics, Inc.: Upward Trend Continues, but Not Without Weakness
-
$MNKD MannKind Corp. Closes Below Vital Support
-
RGIN RunUp Valuation
-
Mike's Notes on RGIN / LCI
-
This Week's Watchlist 1/31/11
-
GTHP RunUp Valuation
-
BioRunDown Coming Soon
-
RGIN - Lesson Learned
-
BioRunUp Live Show
-
Vote on How/ When Trade Alerts Should be Issued
-
This Week's Watchlist 2/7/11
-
XNPT Notes - PDUFA Date of 4/6/11
-
XNPT Valuation
-
Announcing BioRunUp Live Webinars
-
$PLX Meets Resistance Again at 10.60
-
$LCI Lannett Grows Revenue and Profits while Awaiting FDA Approvals
-
Interview on TraderInterviews.com
-
BioRunUp Research Article – Overview of 2010 - Part 1
-
OPTR - Recent Dilution Creates Entry Point for 4/5/11 FDA Panel
-
MNKD Video Trade Review
-
In-Depth Technical Analysis of $OPTR
-
This Week's Watchlist 2/22/11
-
OPTR Valuation
-
Mark Your Calendars for These Two July Trades
-
BioRunUp Research Article – Overview of 2010 (2/2)
-
Its Almost ASCO Season....
-
$CLDA: Pulling Back to the Recent Trend Line
-
TSPT Valuation
-
NEOP Update
-
3/3/11 Webcast Available for 'On-Demand' Viewing
-
KOOL - Recent Dilution and Notes
-
This Week's Catalyst Calendar Summary
-
GTHP Shares Dip After Press Release
-
NEOL.PK Files NDA for Fentanyl Spray
-
Mike's Notes on PSDV
-
SPPI RunUp Valuation
-
BIOD Presentation 3/16 Creates Trading Opportunities
-
Mike's Decision to Sell LCI
-
$AMRN: Can Buyers Break this Downward Channel?
-
Week of 3/10/11 Catalyst Summary
-
IRIS International Stock Notes
-
Will $XNPT Find a Bottom?
-
This Week's Watchlist 3/14/11
-
$BIOD - Biodel Lays Out Clear Clinical and Regulatory Path for Linjeta
-
$ANX Run-Up Valuation
-
LCI Presentation Summary with FDA Updates
-
XNPT - Time to Bail or Time to Buy?
-
LCI - FDA Inspection Update & Pending Decisions
-
OPTR - Picking up Momentum Before its 4/5 FDA Panel
-
Last Week's Catalyst Calendar Summary
-
This Week's Watchlist 3/28/11
-
BMTI BioMimetic - FDA Advisory Panel 5/12/11
-
$SPPI Near Resistance with Upcoming PDUFA
-
Live Webinar Today at 4:30pm EST
-
PTIE Gains 50%+ in the Previous 2 Months
-
Options Trading Idea for PTIE
-
ACUR Run-Up Valuation
-
Last Week's Catalyst Calendar Summary 3/28/11
-
This Week's Watchlist 4/4/11
-
Vote on the Outcome of This Week's FDA Catalysts
-
Update on $AMRN Timeline - Notes
-
$AMRN Finally Showing Some Life
-
FCSC Refresher
-
Conference Call
-
Highlights from Last Week's Catalyst Calendar Updates
-
This Week's Watchlist 4/11/11
-
BioRunUp Subscribers - Please Read
-
$KOOL Multiple Catalysts in Place to Heat up ThermoGenesis Shares
-
$KOOL $LCI FDA Catalyst Updates
-
$PLX FDA Catalyst Update
-
This Week's Watchlist 5/23/11
-
This Week's Watchlist 4/18/11
-
Highlights from Last Week's Clinical and Regulatory Calendar
-
An Update on Anika Therapeutics (NASDAQ:ANIK)
-
Three Upcoming Catalysts that have 50% Gain Potential
-
$TTNP Previewing Titan Pharma’s Phase 3 Clinical Catalyst
-
BioRunUp Survey Results
-
Last Week's Catalyst Calendar Summary 4/22/11
-
This Week's Watchlist 4/25/11
-
PTIE - Run-Up Valuation
-
Video of BioRunUp Mobile
-
PCRX - Run-Up Valuation
-
$PCRX -- A Primer on Pacira Pharma
-
$PATH NuPathe Awaits FDA Decision for Migraine Skin Patch
-
ACUR Options Trade Strategy
-
$CLSN Celsion Strengthens Balance Sheet Ahead of Interim Phase 3 Clinical Data
-
$ANX Adventrx Poised for Run-Up into FDA Decision
-
$SPPI Announces Record Profit ahead of FDA Decision
-
Clinical and Regulatory Catalyst Calendar Updates
-
This Week's Watchlist 5/2/11
-
Mike's Trading Account Updates
-
$ACUR $PTIE - $PFE Previewing a Pair of Pain Drug FDA Decisions
-
$EXAS EXACT Sciences Prepares to Begin Pivotal Trial for DNA-Based Colon Cancer Screening Test
-
Opinion Piece
-
$NDX: Lower Momentum on the Nasdaq's Recent Swing Higher
-
$ANIK Anika Posts 1Q11 Sales Decline on One-Time Delay, FDA Reply for Monovisc Expected in 60 Days
-
$KOOL ThermoGenesis Narrows Net Loss by 40%, Posts 8% Revenue Growth, Expects FDA 510(k) Update Soon
-
PATH Run-Up Valuation
-
This Week's Catalyst Summary
-
This Week's Watchlist 4/9/11
-
$BPAX Key Late-Year FDA, Clinical Trial Catalysts Upcoming for BioSante
-
$CLDX Diversified Immunotherapy Pipeline in Development by Celldex
-
$LCI Lannett Results Lag Year-Ago Period Due to FDA Approval Delays
-
Tune into Livestock Today at 1pm EST
-
$MNKD Conference Call Preview
-
Mark and Mike on Livestock
-
Clinical and Regulatory Catalyst Updates
-
This Week's Watchlist 5/16/11
-
IGXT Notes and NDA Filing
-
$AFFY Affymax Prepares to File for FDA Approval of Once-Monthly Anemia Drug
-
Biotech Trading Book Shipping TODAY
-
Reminder - BioRunUp Webinar Today at 430pm EST
-
$OPTR Running Up as 5/30 PDUFA nears
-
$OSIR Osiris Awaits Health Canada Decision for Prochymal
-
$ZGNX Zogenix Phase 3 Pain Drug Results Expected During 3Q11
-
This Week's Catalyst Calendar Summary - 5/21/11
-
THREE Amazing Experiences
-
OPTR Post-PDUFA Option Play Strap Strategy
-
$VRML Vermillionaires Hoping for an Encore
-
PSDV Update 5/24/11
-
$VRML Update on Vermillion and ACOG Guidelines
-
If You Cant Beat Them, Join Them
-
Video - $OPTR Trade Review
-
OPTR - Random Thoughts
-
This Week's Watchlist - 5/31/11
-
New Feature! Alerts sent to your IM or Email
-
$ASTM to Present Top-Line 12-Month RESTORE-CLI Results TOMORROW
-
$CTIC Bio-Financing Specialist Set to Disappoint Investors, Again
-
$APRI Apricus Bio Prepares for Trio of Phase 3 Trials in 2012
-
OREX 6/3 Conference Call Provides Trading Opportunities
-
OREX Refresher
-
Reminder - Webinar today 4:30pm EST
-
This Week's Catalyst Calendar Updates Summary
-
OREX Trade Review Video
-
This Week's Watchlist 6/6/11
-
Learn to Trade Options Videos
-
$DVAX Dynavax Poised for Run-Up into Phase 3 HBV Vaccine Trial Results
-
$PSDV pSivida Poised for Another Run-Up into FDA Decision
-
Russell Index Reconstitution 2011 - What Does it Mean?
-
$PCRX: A Momentum Play
-
BioRunUp.com Sponsors Clark Richardson in his first PGA Event
-
This Week's Watchlist 6/13/11
-
$VRUS Shares of Pharmasset Continue to Surge on HCV Drug Pipeline
-
Mike’s Trading Account Updates
-
$OMER Omeros Looks to Rebound from Phase 3 Trial Setback
-
IMPORTANT - Please Read
-
$PATH NuPathe’s Zelrix: Market Sizing and Valuation
-
Vote on Trade Notifications
-
Mark's "Game Plan" for $ACUR
-
This Week's Catalyst Calendar Summary 6/17/11
-
This Week's Watchlist 6/20/11
-
$ACUR and $PFE Announce FDA Approval of Oxceta
-
$AMRN Chart and Technical Analysis
-
$PATH Shares of NuPathe Likely to Rebound as FDA Decision Run-Up Trade
-
$ACUR Trade Review Video
-
$REGN Multiple Late-Stage Clinical, FDA Catalysts Upcoming for Regeneron Pharma
-
Technical Analysis of $CLSN
-
New Feature for BioRunUp Subscribers
-
$VVUS Expected to File NDA for Avanafil Within Days
-
Technical Analysis of $BPAX
-
$FCSC Trade Review Video
-
This Week's Catalyst Calendar Summary 6/24/11
-
Technical Analysis of $VVUS
-
This Week's Watchlist 6/27/11
-
$LCI Lannett Drops after FDA Approval with Additional Decisions Pending
-
$DRRX Durect Poised for Rebound and Run-Up into Phase 3 Trial Results
-
Technical Analysis of $PATH
-
From $2k to $250k in 2 Years
-
$TSPT Analyst Report
-
$IGXT Chart Analysis
-
This Week's Catalyst Calendar Summary 7/3/11
-
This Week's Watchlist 7/5/11
-
$PLX Protalix Prepares to file NDA for Taliglucerase alfa
-
$IGXT IntelGenx Seeking to Deliver FDA Approval
-
$NABI Smoking Cessation Vaccine Phase 3 Results Expected During 2H11
-
$CLSN Run-Up Valuation
-
$PCRX Technical Analysis
-
Biotech Buying Strategy Concept
-
VVUS Chart Analysis
-
$TSPT Trade Review Video
-
This Week's Catalyst Calendar Summary 7/8/11
-
This Week's Watchlist 7/11/11
-
Mike's Portfolio Revamp, New Trading Strategy
-
$ARRY Developing Wide Array of Cancer Treatments with Upcoming Clinical Catalysts
-
$KERX Strengthens Balance Sheet with Trio of Phase 3 Clinical Trials Ongoing
-
$THLD Poised to Begin Pivotal Trial and Report Phase 2 Cancer Drug Data
-
$DVAX Chart Technicals
-
$ANDS Poised for Rebound, Run-Up into Phase 2 Results for Pair of HCV Drugs
-
IGXT Run-Up Valuation
-
This Weeks Catalyst Calendar Summary 7/16/11
-
This Week's Watchlist 7/18/11
-
$IGXT Technical Analysis
-
6 Biotechs to Trade During the 2nd Half of 2011
-
$ANIK Poised to Report Strong Results and Provide Monovisc FDA Update
-
$BIOD Biodel Looks to Rebound from FDA Setback
-
Update on $BDSI BioDelivery Sciences pending Phase 3 programs
-
Who Wants to go to Vegas?
-
$GENT Gentium Awaits a Pair of Regulatory Approval Decisions
-
BPAX Run-Up Valuation
-
Weekly Catalyst Calendar Summary 7/22/11
-
This Week's Watchlist 7/25/11
-
$SGEN Chart Analysis
-
$RPTP Video Trade Review
-
Part 1 of 7/25/11 Webinar
-
$PSDV Chart Analysis
-
This Weeks Catalyst Calendar Summary 7/29/11
-
This Week's Watchlist 8/1/11
-
$LCI Lannett Share Price Lags Despite Four FDA Approvals in Five Weeks
-
Marks Portfolio Revamp
-
$VRML Vermillion Posts Product Sales Growth with Study Results Pending
-
Marks Portfolio Revamp #2
-
$CLDX Celldex Provides Update on Cancer Immunotherapy Pipeline
-
Market Panic May Create Buying Opportunities
-
$YMI Key Clinical Trial Data Expected in December for YM Bio
-
This Week's Catalyst Calendar Summary 8/5/11
-
This Week's Watchlist 8/8/11
-
$EXAS Chart Analysis
-
UPDATED - Adjustment of Run-Up Price Targets
-
$ONTY Chart Analysis
-
This Week's Watchlist 8/15/11
-
$VVUS Vivus Advances Late-Stage Obesity, ED Drug Candidates
-
$ANIK An Update on Anika Therapeutics
-
$ARRY Expanded Array of Clinical Trials and Partnerships
-
$ANDS Anadys Investors Await HCV Drug Clinical Trial Results
-
$BPAX Updated Technical Analysis
-
The BioRunUp Book
-
This Week's Catalyst Calendar Updates 8/19/11
-
This Week's Watchlist 8/22/11
-
$BIOD Biodel Poised to Select Lead Rapid-Acting Insulin for Further Development
-
$EXAS EXACT Sciences Initiates Pivotal Study for Colon Cancer Screening Test
-
CLSN - Important Clarification
-
Special BioRunUp NYC Meetup for Vegas Conference Attendees
-
This Weeks Catalyst Calendar Updates
-
This Week's Watchlist 8/29/11
-
A Closer Look at $ARRY's Upcoming Clinical Trials
-
$NEOP Stock Chart Analysis
-
$AEZS Technical Analysis, Positive Divergence
-
$TNGN Spec Buy of Tengion for Organ Regeneration Pipeline
-
$PSDV pSivida Poised for Another Run-Up into FDA Decision, Round Two
-
$AIS RunUp Valuation (PDUFA - 12/8/11)
-
This Week's Catalyst Calendar Summary 9/2/11
-
This Week's Watchlist 9/6/11
-
$PCRX Pacira Prepares for Early 2012 Pain Drug Launch with FDA Decision Pending
-
$LCI Lannett Poised for Growth, FDA Approvals in New Fiscal Year
-
$OMER Omeros Poised to Rebound from Phase 3 Clinical Trial Setback
-
$POZN Two Approved Products, Pending Phase 3 Results and Strong Balance Sheet for POZEN
-
$DRRX Durect Poised for Rebound Ahead of Phase 3 Results
-
Another Look at Vermillion $VRML
-
This Week's Watchlist 9/12/11
-
This Weeks Catalyst Calendar Summary 9/11/11
-
Next Week's Webinar
-
$YMI Chart Analysis
-
$KOOL ThermoGenesis Narrows Loss, Targets Emerging Markets for Growth
-
$EXAS Cologuard Pivotal Study Underway as Product Development Continues
-
$NKTR Multiple Clinical Trial Catalysts for Nektar in 2012
-
This Weeks Catalyst Calendar Summary 9/18/11
-
$EXEL Increased Volatility and Likely Run-Up for Exelixis into Phase 3 Results
-
9/19/11 - Monday's Webinar Available for On-Demand Viewing
-
$PCRX Stock Chart Analysis
-
$POZN Stock Chart Analysis
-
$EXEL Trade Review Video
-
$EXAS Stock Chart Analysis
-
Last Week's Catalyst Calendar Summary 9/25/11
-
This Week's Watchlist 9/26/11
-
$TZYM Tranzyme Poised to Report Data for a Pair of GI Drugs in 2012
-
$ZGNX Zogenix Poised to File for Pain Drug FDA Approval in Early 2012
-
$KERX Keryx Well Capitalized to Reach Trio of Phase 3 Clinical Trial Catalysts
-
$YMI YM Bio Poised for Run-Up into Key Data in December - Update
-
$TLON No Plans to Seize upon this Cancer Biotech
-
$CHTP Key FDA and Clinical Trial Catalysts Upcoming for Chelsea Therapeutics
-
Options Trading DVD Coming Soon!
-
$BDSI Phase 3 Trial Disappoints, but Additional Catalysts Pending
-
This Week's Catalyst Calendar Summary - 9/30/11
-
This Week's Watchlist 10/3/11
-
Webinar 10/6/11
-
$THLD Pivotal Cancer Study Underway, Earlier Stage Results Expected by Year-End
-
$ARRY Extensive Pipeline Offers Multiple Chances at Success for Array
-
Mark's New Trades 11/2/11
-
$TSPT - Upcoming PDUFA Date Creates Trading Opportunites
-
View 10/6/11 Webinar on Demand
-
New Trade for 10/7/11
-
$CYCC Technical Analysis
-
This Week's Watchlist 10/10/11
-
This Week's Catalyst Calendar Summary - 10/9/11
-
New Trade for 10/12/11
-
New Trade for 10/10/11
-
2010 Annual Subscribers- How to Renew Your BioRunUp Subscription
-
New Trade 10/11/11
-
$ECTE Developing Needle-Free Solutions for Drug Delivery and Diabetics
-
Last Week's Catalyst Calendar Summary 10/15/11
-
This Week's Watchlist 10/17/11
-
$ANDS Roche to Acquire HCV Drug Developer Anadys for 256% Premium
-
Exclusive Interview with Mangrove Partners' Nathaniel August (CLSN)
-
Webinar 10/20/11
-
New Long Positions for Mike
-
New Trades 10/19/11
-
$AMRN Stock Chart Technical Analysis
-
$RGRX - Key Clinical Data to be Released Week of 10/31/11
-
This Week's Watchlist 10/25/11
-
$EXEL Technical Stock Chart Analysis
-
$PCRX PDUFA 10/28/11 - Trading Gameplan
-
$EXEL FDA Approval Filing and New Phase 3 Trials Planned for Cabo
-
10/31/11 Webinar
-
Webinar - MONDAY 10/31/11 at 4:30pm EST
-
This Week's Catalyst Calendar Summary - 10/29/11
-
This Week's Watchlist 10/31/11
-
$VTUS Phase 3 Results for Pair of GI Drugs Expected in First Two Quarters of 2012
-
New Trade - Video Explanation
-
$NEOP Technical Chart Analysis
-
Mark's Notes - PCRX FDA Approval
-
New Trades for Mike
-
$FOLD Low Valuation for Amicus Ahead of 2012 Phase 3 Clinical Trial Catalysts
-
$TRGT Targacept Set to Report First of Five Phase 3 Trials in November
-
How to Receive SMS (Text) Alerts from @BioRunUpTrades via Twitter
-
Mark's New Trade 11/3/11
-
This Week's Watchlist 11/7/11
-
$ANIK Anika Reports Strong 3Q11 Sales and Profit Growth
-
This Week's Catalyst Calendar Summary - 11/6/11
-
IGXT - Mark's Trading Gameplan
-
$RMTI Dialysis Product Specialist Awaits Key SFP Clinical Trial Results
-
Updated $BPAX / $AIS Gameplan Trading Video
-
NOTICE - Webinar TUESDAY 11/15/11 4:30pm EST
-
CLSN CC Live Blog
-
New Trades and Portfolio Recap for Mike
-
New ASH Run-Up Buy for Mike
-
This Week's Watchlist 11/14/11
-
IGXT / ALIM Trade Review Video
-
This Week’s Catalyst Calendar Summary 11/12/11
-
$YMI Stock Chart Analysis
-
$DSCO Seeking FDA Approval for Premature Infant Lung Drug
-
$OMER Pair of Phase 3 Results Expected Through Mid-2012 for Omeros
-
11/15/11 Webinar Available On-Demand
-
New Long Position for Mike
-
Mark's $CLSN Video Trading Gameplan
-
This Week's Catalyst Calendar Summary - 11/19/11
-
This Week's Watchlist 11/21/11
-
$CBRX FDA Approval Key to Achieving Sustained Profitability
-
$XNPT Several Clinical and Regulatory Catalysts Pending for XenoPort
-
$CYCC Stock Chart Analysis
-
New Trade for Mark 11/22/11
-
$YMI Video Review
-
$POZN Major Catalysts Pending for Pozen in 2012
-
$EXAS Stock Chart Analysis
-
Mark's TSPT Trading Gameplan Video
-
This Week's Watchlist 11/28/11
-
Introducing "How To Trade Options" 50% off Pre-Sale
-
Webinar Thursday 12/1 at 4:30pm EST
-
$AFFY / $ALXA Trading Gameplan Video
-
New Long Position for Mike
-
$TSPT Daytrade Video Review
-
$ASTX Cancer Biotech Trading Near Cash with Pending FDA (sNDA) Decision
-
On-Demand Webinar from 12/1/11
-
12-2-11 Catalyst Calendar Summary
-
This Week's Watchlist 12/5/11
-
$VRUS $GILD $VRTX $INHX $IDIX $ACHN Picking a Horse in the HCV Drug Developer Race
-
$ANAC Strong Balance Sheet, Pharma Partnerships and Multiple Clinical Catalysts for Anacor
-
@BioRunUpTrades Twitter Updates
-
New Long Position for Mike
-
AIS / BPAX Trading Gameplan
-
$AIS Stock Chart Analysis
-
$TZYM Extends $BMY Pact, Expects Initial Phase 3 Results in Spring 2012
-
New Long Position for Mike
-
What a Crazy Morning! $AIS $ALXA $AFFY Video Review
-
This Week's Watchlist 12/12/11
-
12/10/11 Catalyst Calendar Summary
-
$LCI Lannett Poised for Sales and Profit Growth in 2012
-
$YMI $ALXA and Mystery Non-Biotech Stock 'Gameplan' Video
-
$CRIS Stock Chart Analysis
-
$ASTX - Well Positioned to Run to its 3/6/12 PDUFA Date
-
New Long Position for Mike
-
12/16/11 Clinical and Regulatory Catalyst Calendar Summary
-
12/15/11 Webinar Available for On-Demand Viewing
-
This Week's Watchlist 12/19/11
-
$NGSX Pain Drug Developer Awaits 1Q12 FDA (sNDA) Decision
-
$NEPT Seeking to Develop a Better Omega-3 Prescription Drug
-
$ANAC Expects to Report Initial Phase 3 Data in Late 2012
-
This Week's Watchlist 12/27/11
-
CORT Run-Up Valuation Study
-
Tax Loss Selling
-
$KOOL Cites Global Economic Crisis, Increased Competition for Weak Results
-
$YMI CYT387 Is Key Value Driver with Multiple Catalysts Expected in 2012
-
No Webinar This Week
-
$BDSI Seeks to Rebound from Phase 3 Setback
-
12/26/11 Catalyst Calendar Summary
-
Trade Review Video 12/29/11
-
This Week's Watchlist 1/2/12
-
This Week's Catalyst Calendar Summary - 12/30/11
-
Spec Trade for Mike Trading at Cash Value with Insider Buying
-
New Trade and Video Gameplan
-
Webinar Tuesday January 10th at 4:30pm EST
-
This Week's Watchlist 1/9/12
-
1/9/12 Clinical and Regulatory Calendar Summary
-
$AMRN Stock Chart Analysis
-
$CRMD Spec Bio Stock with Insider Buying and CE Mark Catalyst
-
$ECTE Symphony Glucose Monitoring System is Key Valuation Catalyst
-
1/10/12 Webinar On-Demand
-
$CRIS Stock Chart Analysis
-
This Weeks Catalyst Calendar Summary 1/13/12
-
This Week's Watchlist 1/17/12
-
$HZNP FDA Decision for Lodotra Is a Trading Catalyst on the Horizon this Summer
-
$KERX Stock Chart Analysis
-
AMLN FDA Pre-Decision Options Trading Plan
-
AMRN Chart Analysis - Video
-
Webinar - Thursday January 26th at 4:30pm EST
-
This Week's Watchlist 1/23/12
-
This Week's Catalyst Calendar Summary - 1/21/12
-
$TSRX Reports Positive Results in First of Two Phase 3 Trials for Antibiotic Drug
-
This Week's Watchlist 1/30/12
-
AMLN Video Gameplan for Monday January 30th
-
This Week's Catalyst Calendar Summary - 1/29/12
-
$DSCO Run-Up Valuation Study
-
$ONTY Stock Chart Analysis
-
Hepatitis C Drug Delivery Stock Trade for Mike
-
$EXAS Key Data for Colon Cancer Screening Test Expected Around 3Q12
-
Trading Options around $CORT 2/17/12
-
2/6/12 Watchlist and Clinical Database Summary
-
BioRunUp Webinar Notice
-
$FRX Late-Stage Pipeline Is Key as Lexapro Patent Cliff Looms
-
New Phase 3 Catalyst Trade for Mike with Strong Balance Sheet
-
New Medical Device Trade for Mike
-
This Week's Watchlist 2/13/12
-
This Week's Catalyst Updates 2/12/12
-
New Diabetes Drug Delivery Trade for Mike and Mark
-
This Week's Watchlist 2/21/12
-
$CORT / $CHTP Video Trading Gameplan
-
About Us
-
Contact Us
-
Home
|
